Trial
NCT03399448
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Pennsylvania
Collaborators
Parker Institute for Cancer Immunotherapy; Gilead Sciences
Condition
Multiple Myeloma
Intervention
NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
Why stopped
Sponsor has terminated trial to pursue other targets.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-22